Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine

Cariprazine is currently approved for the treatment of patients with schizophrenia (USA and EU), and for manic, depressive, and episodes with mixed features in bipolar I disorder (USA): several randomized controlled studies have also explored its efficacy in patients with major depressive disorder....

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Borjanka Batinic, Ivan Ristic, Milica Zugic, David S. Baldwin
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	cariprazine D3/D2 partial agonist schizophrenia bipolar I disorder major depressive disorder Psychiatry RC435-571
Acceso en línea:	https://doaj.org/article/75c9ae4a9cf5413babeb8d494ee13cd4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:75c9ae4a9cf5413babeb8d494ee13cd4
record_format	dspace
spelling	oai:doaj.org-article:75c9ae4a9cf5413babeb8d494ee13cd42021-11-30T11:47:23ZTreatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine1664-064010.3389/fpsyt.2021.784370https://doaj.org/article/75c9ae4a9cf5413babeb8d494ee13cd42021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fpsyt.2021.784370/fullhttps://doaj.org/toc/1664-0640Cariprazine is currently approved for the treatment of patients with schizophrenia (USA and EU), and for manic, depressive, and episodes with mixed features in bipolar I disorder (USA): several randomized controlled studies have also explored its efficacy in patients with major depressive disorder. This review summarizes its current therapeutic uses and potential advantages for treating the main symptoms of schizophrenia, bipolar I and major depressive disorder, considering its pharmacodynamic properties, efficacy, and tolerability. Its predominantly D3 receptor preferring affinity, with functional selectivity according to the prevailing neuronal environment, contributes to its efficacy across a wide array of psychopathological symptoms (including reality distortion, disorganized thought, negative symptoms, mood disturbance, anhedonia, and cognitive impairment), and to a favorable side effect profile. Cariprazine may be a “drug of choice” in patients with predominant negative and cognitive symptoms of schizophrenia, as well as those with metabolic syndrome. Further investigation of its relative efficacy when compared to aripiprazole or other active comparators is warranted. Its effectiveness in the treatment of bipolar mania, bipolar I depression and bipolar I episodes with mixed features, with minimal accompanying metabolic changes is well-established. The longer half-life and delayed time to relapse in patients diagnosed with schizophrenia when compared to other second-generation antipsychotics represent other advantages, given the high rates of non-adherence and frequent relapses seen in clinical practice. Its efficacy in overlapping symptom domains in other major psychiatric disorders appears promising.Borjanka BatinicBorjanka BatinicIvan RisticIvan RisticMilica ZugicDavid S. BaldwinDavid S. BaldwinFrontiers Media S.A.articlecariprazineD3/D2 partial agonistschizophreniabipolar I disordermajor depressive disorderPsychiatryRC435-571ENFrontiers in Psychiatry, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	cariprazine D3/D2 partial agonist schizophrenia bipolar I disorder major depressive disorder Psychiatry RC435-571
spellingShingle	cariprazine D3/D2 partial agonist schizophrenia bipolar I disorder major depressive disorder Psychiatry RC435-571 Borjanka Batinic Borjanka Batinic Ivan Ristic Ivan Ristic Milica Zugic David S. Baldwin David S. Baldwin Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine
description	Cariprazine is currently approved for the treatment of patients with schizophrenia (USA and EU), and for manic, depressive, and episodes with mixed features in bipolar I disorder (USA): several randomized controlled studies have also explored its efficacy in patients with major depressive disorder. This review summarizes its current therapeutic uses and potential advantages for treating the main symptoms of schizophrenia, bipolar I and major depressive disorder, considering its pharmacodynamic properties, efficacy, and tolerability. Its predominantly D3 receptor preferring affinity, with functional selectivity according to the prevailing neuronal environment, contributes to its efficacy across a wide array of psychopathological symptoms (including reality distortion, disorganized thought, negative symptoms, mood disturbance, anhedonia, and cognitive impairment), and to a favorable side effect profile. Cariprazine may be a “drug of choice” in patients with predominant negative and cognitive symptoms of schizophrenia, as well as those with metabolic syndrome. Further investigation of its relative efficacy when compared to aripiprazole or other active comparators is warranted. Its effectiveness in the treatment of bipolar mania, bipolar I depression and bipolar I episodes with mixed features, with minimal accompanying metabolic changes is well-established. The longer half-life and delayed time to relapse in patients diagnosed with schizophrenia when compared to other second-generation antipsychotics represent other advantages, given the high rates of non-adherence and frequent relapses seen in clinical practice. Its efficacy in overlapping symptom domains in other major psychiatric disorders appears promising.
format	article
author	Borjanka Batinic Borjanka Batinic Ivan Ristic Ivan Ristic Milica Zugic David S. Baldwin David S. Baldwin
author_facet	Borjanka Batinic Borjanka Batinic Ivan Ristic Ivan Ristic Milica Zugic David S. Baldwin David S. Baldwin
author_sort	Borjanka Batinic
title	Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine
title_short	Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine
title_full	Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine
title_fullStr	Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine
title_full_unstemmed	Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine
title_sort	treatment of symptom clusters in schizophrenia, bipolar disorder and major depressive disorder with the dopamine d3/d2 preferring partial agonist cariprazine
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/75c9ae4a9cf5413babeb8d494ee13cd4
work_keys_str_mv	AT borjankabatinic treatmentofsymptomclustersinschizophreniabipolardisorderandmajordepressivedisorderwiththedopamined3d2preferringpartialagonistcariprazine AT borjankabatinic treatmentofsymptomclustersinschizophreniabipolardisorderandmajordepressivedisorderwiththedopamined3d2preferringpartialagonistcariprazine AT ivanristic treatmentofsymptomclustersinschizophreniabipolardisorderandmajordepressivedisorderwiththedopamined3d2preferringpartialagonistcariprazine AT ivanristic treatmentofsymptomclustersinschizophreniabipolardisorderandmajordepressivedisorderwiththedopamined3d2preferringpartialagonistcariprazine AT milicazugic treatmentofsymptomclustersinschizophreniabipolardisorderandmajordepressivedisorderwiththedopamined3d2preferringpartialagonistcariprazine AT davidsbaldwin treatmentofsymptomclustersinschizophreniabipolardisorderandmajordepressivedisorderwiththedopamined3d2preferringpartialagonistcariprazine AT davidsbaldwin treatmentofsymptomclustersinschizophreniabipolardisorderandmajordepressivedisorderwiththedopamined3d2preferringpartialagonistcariprazine
_version_	1718406628922884096

Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine

Ejemplares similares